AHK-Cu Peptide: What It Is, the Hair Growth Evidence and What's Still Unknown
Start with our pillar guide: Best Peptides for Skin: Peptide Ingredients in Skincare Ranked by Evidence, or browse all Peptide Science articles.
AHK-Cu peptide is a lab-made copper peptide, alanine-histidine-lysine bound to copper, sold mainly in hair serums. The only AHK-specific study we found is a 2007 lab study on human hair follicles and cells grown outside the body (Pyo et al., 2007). No human trials have tested AHK-Cu for hair or skin.
Evidence: Lab / animal only.
Key takeaways
- The only AHK-Cu-specific peer-reviewed study we found is a 2007 lab study. It reported that AHK-Cu at 10⁻¹² to 10⁻⁹ M lengthened human hair follicles kept alive outside the body and made dermal papilla cells multiply (Pyo et al., 2007).
- In that 2007 study, AHK-Cu at 10⁻⁹ M lowered the number of dying dermal papilla cells, but the abstract says the decrease "was not statistically significant" (Pyo et al., 2007).
- A 1993 review reported that an unnamed copper-binding peptide, PC1031, enlarged follicles in fuzzy rats with an effect "similar to that of topical minoxidil." PC1031 is not identified as AHK-Cu (Uno & Kurata, 1993).
- A 2026 evidence-mapping review treats canonical GHK-Cu, GHK-derived copper peptides and non-GHK copper peptides as separate groups, so AHK-Cu can't borrow GHK-Cu's evidence (Mateescu et al., 2026).
- In 2,660 routine patch tests, 3.53% reacted to copper vs 21.02% to nickel. These are copper-salt results, not AHK-Cu results (Wöhrl et al., 2001).
AHK-Cu belongs to the copper peptide family. Its far better-studied relative is GHK-Cu, and our guide to copper peptides for skin covers that molecule's human data, absorption and layering rules. This page sticks to what is known, and not known, about AHK-Cu itself.
What is AHK-Cu peptide?
AHK-Cu peptide is a tripeptide, meaning a chain of 3 amino acids (alanine, histidine and lysine), bound to a copper(II) ion. The 2007 hair study names it L-alanyl-L-histidyl-L-lysine-Cu2+ (Pyo et al., 2007).
AHK-Cu differs from GHK-Cu by a single amino acid: alanine sits where GHK-Cu has glycine. That small change makes it a separate molecule, so results for one can't be assumed for the other. Our AHK-Cu vs GHK-Cu comparison sets the two side by side.
Naming is where buyers get confused. GHK-Cu's INCI name (the International Nomenclature of Cosmetic Ingredients, the standardized name on ingredient lists) is copper tripeptide-1. Sellers often label AHK-Cu "copper tripeptide-3," but we could not confirm that name in the EU CosIng inventory ourselves, so we don't treat it as an official INCI name. The safest check is a product that spells out the sequence, such as "AHK-Cu" or "alanine-histidine-lysine copper."
What is AHK-Cu peptide used for?
AHK-Cu peptide is sold mainly in hair and scalp serums marketed for thicker or fuller hair; our review of The Ordinary's hair density serum checks one such formula against its ingredient studies. Skin claims for it, such as collagen and firmness, are usually borrowed from GHK-Cu research rather than from AHK-Cu studies.
The hair positioning traces back to the 2007 follicle study. That paper's background section also states that the tripeptide-copper complex stimulates dermal fibroblast proliferation and production of VEGF (vascular endothelial growth factor, a signal involved in blood-vessel growth) (Pyo et al., 2007). That line is background context, not a skin experiment with AHK-Cu.
A recurring question in hair-loss and skincare communities is whether AHK-Cu is "the hair copper peptide" and GHK-Cu "the skin one." That split reflects how products are marketed. Neither use of AHK-Cu has been tested in a human trial. For the wider hair evidence, most of which is on GHK-Cu, see our review of copper peptides for hair, and for hair peptides beyond copper, our guide to peptides for hair growth.
Evidence: Lab / animal only.
Does AHK-Cu peptide work for hair growth?
We don't know. The only AHK-Cu hair evidence is a single 2007 study on human follicles and cells in a lab dish, and no study has tested AHK-Cu on anyone's scalp.
The 2007 follicle study
Pyo and colleagues kept human hair follicles alive in organ culture (ex vivo, meaning outside the body) and separately grew dermal papilla cells (DPCs), the specialized fibroblasts at the base of the follicle that help drive hair growth (Pyo et al., 2007). AHK-Cu at 10⁻¹² to 10⁻⁹ M stimulated follicle elongation ex vivo and DPC proliferation in vitro.
At 10⁻⁹ M, AHK-Cu reduced the number of apoptotic (dying) DPCs, "but this decrease was not statistically significant," the abstract says. The Bcl-2/Bax ratio, a balance between proteins that protect cells and proteins that push them toward death, rose. Cleaved caspase-3 and PARP, markers of cell death in progress, fell. The authors "proposed" that AHK-Cu promotes follicle growth by boosting DPC proliferation and preventing apoptosis.
The abstract doesn't state funding or conflicts, the number of donors or the follicle measurements, and we did not verify the full text. The concentrations are picomolar to nanomolar in a culture dish. They can't be converted into a percentage in a serum, so any product claiming a "clinical dose" of AHK-Cu has no human data behind that figure.
| Feature | Measured (lab) | Not tested |
|---|---|---|
| Hair growth | Follicle elongation ex vivo | Hair growth in people |
| Cells | DPC proliferation in vitro | Effects on a living scalp |
| Cell death | Apoptosis markers (Bcl-2/Bax, caspase-3, PARP) | Shedding, in either direction |
| Application | Peptide added to culture medium | Scalp application or penetration |
| Dose | 10⁻¹² to 10⁻⁹ M | Dose in a product (% or mg) |
| Comparison | None | Comparison with minoxidil |
Bottom line: A lab signal in follicles and cells. It does not show that an AHK-Cu serum grows hair.
Animal and copper-peptide studies (not AHK-Cu)
Older animal work involves copper peptides, but none of it identifies AHK-Cu.
- Mice, peptide unnamed. A 1991 paper titled "The hair follicle-stimulating properties of peptide copper complexes" reports results in C3H mice (Trachy et al., 1991). The record has no abstract and doesn't name the peptide. One author, Loren Pickart, discovered GHK. We can't say this was AHK-Cu.
- Fuzzy rats, compared with minoxidil. A 1993 review of animal work states that a copper-binding peptide called PC1031 enlarged follicles on the back skin of fuzzy rats and that "the effect was similar to that of topical minoxidil" (Uno & Kurata, 1993). PC1031's identity isn't given, and this was animal skin. It doesn't show that AHK-Cu matches minoxidil.
- Human injections, multi-ingredient. An open-label, single-arm pilot study treated 1,000 patients with scalp injections every 3 weeks for 8 sessions. The formulation contained VEGF, bFGF, IGF, KGF, thymosin β4 and copper tripeptide-1 (GHK-Cu, not AHK-Cu). Hair fall was reduced in 83% on a pull test, total hair count rose at 1 year (P=0.002), and the injections were well tolerated (Kapoor & Shome, 2018). Funding is not reported in the abstract. With no control group and 6 active ingredients, the result can't be credited to the copper peptide.
- GHK-Cu eyebrows. A 2026 evidence map mentions an 18-participant split-face eyebrow study of GHK-Cu reporting positive cosmetic hair outcomes, but notes it didn't define GHK-Cu speciation or local exposure (Mateescu et al., 2026). That is GHK-Cu, not AHK-Cu.
If your hair started thinning during GLP-1 weight loss, the causes and time course are different; see our guide to hair loss on Ozempic and what helps.
| Pyo et al., 2007 (AHK-Cu, lab/ex vivo) | Not reported in abstract | Not reported in abstract | 10⁻¹² to 10⁻⁹ M in culture | Follicle elongation ex vivo; DPC proliferation; apoptosis drop not significant |
| Trachy et al., 1991 (unnamed copper peptide, mice) | Not reported (no abstract) | Not reported | Not reported | Title reports follicle-stimulating properties in C3H mice |
| Uno & Kurata, 1993 (PC1031, fuzzy rats) | Not reported in abstract | Not reported in abstract | Topical; amount not reported | Follicular enlargement, similar to topical minoxidil; peptide not identified |
| Kapoor & Shome, 2018 (multi-ingredient injections, humans) | 1,000 | 8 sessions, every 3 weeks; hair count at 1 year | Growth factors + copper tripeptide-1, intradermal | Hair fall reduced in 83% (pull test); hair count up (P=0.002); open-label, no control |
| Human trials of AHK-Cu (hair or skin) | None found | None | None | No data |
Pyo et al., 2007 (AHK-Cu, lab/ex vivo)
Result: Follicle elongation ex vivo; DPC proliferation; apoptosis drop not significant
Human follicles in organ culture and cultured dermal papilla cells. Funding not stated in abstract. The only AHK-specific study found.
Lab/ex vivo: AHK-Cu yes. Animal: unnamed copper peptides only. Human: none for AHK-Cu.
Evidence: Lab / animal only.
Does AHK-Cu peptide do anything for skin?
No study has tested AHK-Cu peptide on skin. The skin claims on AHK-Cu products come from GHK-Cu research, and the reviews that map that research keep the two molecules apart.
A 2026 systematic evidence-mapping review explicitly separates canonical GHK-Cu, GHK-derived copper peptides and non-GHK copper-peptide systems (Mateescu et al., 2026). Even for GHK-Cu, it found clinical evidence "remains sparse," and a 13-participant study after CO2 laser treatment was negative on objective endpoints. AHK-Cu falls in a separate group with none of that clinical history.
Absorption is another open question. GHK-Cu "is a fairly hydrophilic compound with limited permeation through the lipophilic stratum corneum," the oily outer layer of skin (Ogórek et al., 2025). In a lab test, almost no GHK-Cu peptide or copper passed through intact human skin in 9 hours, while microneedle pretreatment raised permeation (Li et al., 2015).
We found no permeation data for AHK-Cu at all. Whether it reaches the follicle or the dermis from a scalp serum is unknown. Our explainer on whether peptides absorb into skin covers the broader penetration problem.
Evidence: Lab / animal only.
Is AHK-Cu peptide safe?
We don't know, because no human safety data exist for AHK-Cu. The closest data are copper patch tests, which use copper salts, not the peptide.
A review of copper hypersensitivity found a weighted average of 3.8% positive patch tests to copper among people with suspected exposure or related symptoms. It describes copper as "a very weak sensitizer" compared with other metals, though it causes clinically relevant allergy in a few selected cases (Fage et al., 2014).
In 2,660 routine patch tests, 3.53% were positive to copper vs 21.02% to nickel, and copper and nickel reactions were strongly linked (Wöhrl et al., 2001). On retesting 26 patients, only 38% reproduced. The authors called positive copper tests "mostly specific" but "usually of low clinical relevance." If you have a known copper or nickel allergy, talk to a dermatologist before trying any copper product.
Shedding is a common worry: some people report extra hair fall after starting copper serums, and others call it a sign the product is working. We found no data on AHK-Cu and shedding either way. For the "copper uglies" story and what it does and doesn't mean, see copper peptides ruined my skin?, and for reactions in general, see copper peptide side effects.
Evidence: Limited. Copper-salt patch tests only; no AHK-Cu data.
Should you buy AHK-Cu powder or inject it?
No. Powders and vials sold as "research use only" are not made for skin or for injection, and AHK-Cu has no human safety data at all.
A 2026 review describes a "gray market" of unapproved peptides, including GHK-Cu, BPC-157 and TB-500, that operates largely outside regulatory oversight. It concludes that "rigorous human safety data are scarce, and there is potential for serious harm to patients" (Mendias & Awan, 2026). AHK-Cu isn't named in that abstract, but research-use powders and injectables are sold through the same kind of channel.
AHK-Cu isn't an approved drug ingredient that we could find. Serums containing it are sold as cosmetics, which make appearance claims and don't go through drug approval. Mixing your own serum adds guesswork about purity, concentration and pH that a finished cosmetic is at least formulated to control.
Evidence: Limited.
How do you use an AHK-Cu peptide serum, and what should you check on the label?
There is no tested routine for an AHK-Cu peptide serum. The practical steps are reading the label carefully and applying the layering rules used for GHK-Cu, which share the same copper chemistry but have never been tested with AHK-Cu.
Layering, by analogy with GHK-Cu. The site's ingredient-conflict rules for GHK-Cu rest on lab chemistry, not skin studies:
- Vitamin C: a copper(II)-ascorbate system generates reactive oxygen species in lab chemistry (Jomova et al., 2023). The cautious approach is vitamin C in the morning and copper at night.
- Acids and benzoyl peroxide: GHK-Cu degraded under oxidative, basic and, to a lesser extent, acidic stress, and was stable at pH 4.5 to 7.4 (Badenhorst et al., 2016). Keep copper apart from low-pH acids and benzoyl peroxide.
- Retinol: metal ions are among the factors that degrade retinol (Wang et al., 2023). Use copper in the morning or on non-retinoid nights.
Minoxidil. No study has tested AHK-Cu together with minoxidil, so we can't tell you whether the pair helps, hurts or does nothing. If minoxidil is part of a treatment plan, raise any add-on with the clinician who manages it.
Evidence: Lab / animal only.
How is AHK-Cu different from GHK-Cu?
AHK-Cu and GHK-Cu differ by one amino acid, alanine vs glycine. GHK-Cu has far more research, though it's still thin: a 2025 review found "a surprising absence of clinical studies" (Mortazavi et al., 2025), and a 2026 systematic review counted 20 studies, 18 preclinical and 2 RCTs (Mokhtar et al., 2026). Because evidence maps treat GHK-Cu and non-GHK copper peptides separately (Mateescu et al., 2026), evidence for one doesn't transfer to the other, and we're preparing a fuller comparison of the two.
Where the evidence stops
- No human trial of AHK-Cu for hair or skin, at any dose.
- No data on how much AHK-Cu a serum should contain; lab molarities can't be mapped to product strengths.
- No penetration data for AHK-Cu, and even GHK-Cu permeates intact skin poorly.
- No data on shedding, time to results, or combinations with minoxidil or retinol.
- No AHK-Cu human safety data; copper-salt patch tests are the nearest proxy.
FAQ
Is AHK-Cu better than minoxidil?
No study has compared AHK-Cu with minoxidil in people. The only minoxidil comparison we found is a 1993 review of rat work in which an unnamed copper peptide, PC1031, had an effect similar to topical minoxidil, and PC1031 is not identified as AHK-Cu. Decisions about hair-loss treatment belong with a dermatologist.
How long does AHK-Cu take to work for hair?
Nobody knows, because no human study has tested AHK-Cu on hair. The 2007 study measured follicle elongation and cell growth in lab culture, and those results don't give a timeline for regrowth on a real scalp.
Can AHK-Cu cause shedding?
We found no data on AHK-Cu and shedding. No human study has tracked shedding with AHK-Cu, so there is no evidence for the claim that shedding means it's working, and none for the claim that it's a side effect.
Can I use AHK-Cu with minoxidil or retinol?
No study has tested AHK-Cu with minoxidil, so we can't say whether the combination helps or harms; ask the clinician who manages your hair-loss treatment. For retinol, lab work shows metal ions can degrade retinol, so the cautious approach used for GHK-Cu is to apply copper in the morning or on non-retinoid nights, but this has never been tested for AHK-Cu.
Is AHK-Cu the same as copper tripeptide-1?
No. Copper tripeptide-1 is the INCI name for GHK-Cu, which has glycine where AHK-Cu has alanine. Vendors often call AHK-Cu copper tripeptide-3, but we could not confirm that name in the EU CosIng inventory ourselves.
Is AHK-Cu FDA approved?
We found no approval and no drug trials for AHK-Cu. Serums containing it are sold as cosmetics, which make appearance claims and don't go through drug approval.
Should I mix AHK-Cu powder or inject it?
No. Research-use-only powders and injectables sit in a gray market where, according to a 2026 review of unapproved peptides, rigorous human safety data are scarce and there is potential for serious harm. AHK-Cu itself has no human safety data at all.
References
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. Ex vivo human follicle organ culture + in vitro dermal papilla cells; n not reported in abstract; funding not stated. https://pubmed.ncbi.nlm.nih.gov/17703734/
- Trachy RE, et al. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Ann N Y Acad Sci. 1991. Animal (mice); no abstract; peptide not identified. https://pubmed.ncbi.nlm.nih.gov/1809108/
- Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993. Review of animal studies (PC1031 in fuzzy rats). https://pubmed.ncbi.nlm.nih.gov/8326148/
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018. Open-label, single-arm, n=1,000; 8 sessions every 3 weeks, 1-year follow-up; multi-ingredient incl. copper tripeptide-1; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/29482481/
- Mateescu DM, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026. Systematic evidence-mapping review. https://pubmed.ncbi.nlm.nih.gov/42797253/
- Ogórek K, et al. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules. 2025. Review. https://pubmed.ncbi.nlm.nih.gov/39795193/
- Li H, et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015. In vitro (human skin, 9 hours). https://pubmed.ncbi.nlm.nih.gov/25690343/
- Mortazavi SM, et al. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025. Narrative review. https://pubmed.ncbi.nlm.nih.gov/39963574/
- Mokhtar J, et al. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J. 2026. Systematic review to March 2026; 20 studies (18 preclinical, 2 RCTs). https://pubmed.ncbi.nlm.nih.gov/42619529/
- Fage SW, et al. Copper hypersensitivity. Contact Dermatitis. 2014. Review of copper patch-test data (copper salts). https://pubmed.ncbi.nlm.nih.gov/25098945/
- Wöhrl S, et al. Copper allergy revisited. J Am Acad Dermatol. 2001. Patch-test series, n=2,660; retest n=26 (copper salts). https://pubmed.ncbi.nlm.nih.gov/11712031/
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. Narrative review; AHK-Cu not named. https://pubmed.ncbi.nlm.nih.gov/41966639/
- Jomova K, et al. The role of redox active copper(II) on antioxidant properties of the flavonoid baicalein: DNA protection under Cu(II)-Fenton reaction and Cu(II)-ascorbate system conditions. J Inorg Biochem. 2023. https://pubmed.ncbi.nlm.nih.gov/37178556/
- Badenhorst T, et al. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016. https://pubmed.ncbi.nlm.nih.gov/25384620/
- Wang PHM, et al. An eco-friendly system for stabilization of retinol: A step towards attending performance with improved environmental respect. Int J Cosmet Sci. 2023. https://pubmed.ncbi.nlm.nih.gov/36853015/
Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. AHK-Cu has not been tested in human studies; talk to a dermatologist about hair loss, and don't inject or ingest products sold for research use.